WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change

WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change WHO and international advocacy organization Global Citizen today signed a memorandum…

Read MoreWHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant…

Read MoreFirst-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced…

Read MoreBayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced…

Read MoreBoehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight